REG - EMV Capital PLC - ProAxsis: Status Update and Proposed Fundraise

EMV CapitalAnnouncement

03/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250203:nRSC5576Va&default-theme=true

RNS Number : 5576V  EMV Capital PLC  03 February 2025

For release: 07:00, 3 February 2024

EMV Capital Plc

(EMVC, Group or the Company)

EMV Capital Backed ProAxsis Ltd Announces Financial and Operational Progress
and Proposed Fundraise

EMV Capital plc (AIM: EMVC), the deeptech and life sciences VC investment
group, is pleased to announce that its portfolio company, ProAxsis Ltd
(ProAxsis), has provided an update on financial and operational progress. It
has also launched a fundraising programme to raise up to £800,000
(Fundraising), to deliver commercial progress towards profitability, following
a significant reduction in losses.

ProAxsis leverages its proprietary protease-targeted technology and NEATstik
platform to address unmet needs in chronic respiratory disease diagnostics.

Summary of financial and operational progress

1.    Revenue growth and efficiency

·     31 December 2024 full-year revenues increased by 92% to £470,000
(provisional, unaudited)

·     Reduced staff costs by 40% and overall operating costs by 28%

·     Losses reduced to £718,000, down by 47% from 2023 results
(provisional, unaudited)

2.    Market expansion and partnerships

·     Strong sales pipeline for 2025, including provisional orders of
£650,000

·   Advanced plans for a clinical study in Chronic Obstructive Pulmonary
Disease (COPD) in partnership with Imperial College London, targeted at
expanding clinical trials

·     Strengthened partnerships with Boehringer Ingelheim, Sanofi, and
University of Dundee

·     Within the Innovate UK-funded NEATstik project, a prototype is
anticipated in April 2025

3.    Grant funding as previously announced

·   Innovate UK SMART Grant awarded alongside CPI, with £333,000
allocated to ProAxsis for advancing the second-generation NEATstik platform

·     Additional grant of £165,000 from LifeArc

 *  Refinement of the scope of the £900k multi-year grant from the Precision
Medicine Consortium

Details of the Fundraising

The Fundraising will be by way of issue of new shares in the capital of
ProAxsis to third party existing and new shareholders syndicated by EMV
Capital Partners Limited, the Company's wholly owned VC and corporate finance
firm. It is anticipated that the Fundraising will close over a number of
tranches during the course of 2025.

ProAxsis has indicated that it intends for the proceeds of the Fundraising
(assuming £800,000 is raised) to be divided as to £500,000 towards core
business activities, and £300,000 towards advancing a COPD clinical study
with Imperial College.

The Group's existing total fully diluted equity holding in ProAxsis is 88.5%
with other assets under management (third party management funds) of an
additional 9.0%. As announced in the Company's interim results for the six
months ended 30 June 2024, the fair value (as at 30 June 2024) of the
Company's stake in ProAxsis is estimated to be £8.0 million, with other
assets under management having an additional fair value of £0.8 million. As
the Fundraising issue price is intended to be unchanged since the previous
fundraising of ProAxsis (announced 15 April 2024) it is anticipated that such
fair value amounts will not be affected by the Fundraising.

Ilian Iliev, CEO of EMVC PLC, commented:

"During 2024, ProAxsis made significant progress in stabilising the business
platform, advancing its commercial development and progressing its clinical
trials plans for the COPD space. Through our value creation services
programme, EMV Capital helped ProAxsis evolve to a leaner and more focused
business. The company is in a good position to enter the next stage of its
development. The current fundraise is aimed at delivering critical clinical
milestones, commercial traction, and significant future value creation and we
look forward to continuing to work alongside ProAxsis to achieve these. "

 

The person responsible for arranging the release of this announcement on
behalf of the Company is Ed Hooper, Executive Director and General Counsel of
the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

-Ends-

 

 For more information, please contact:
 EMV Capital plc                                                             via Rosewood
 Ilian Iliev, CEO

 Panmure Liberum (UK) Limited (NOMAD and Broker)                             +44 (0)20 7886 2500
 Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 Rosewood (Financial PR)                                                     +44 (0)20 7653 8702
 John West / Llew Angus / Lily Pearce

 

About EMV Capital plc (EMVC)

EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life
sciences venture capital investment group with an international portfolio of
high-growth companies.

With a strategic focus on generating superior returns for investors from the
fast-growing sectors and technologies that will define our future; EMV Capital
invests in, manages and strengthens early stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its
portfolio companies, creating an evergreen structure that supports extensive
growth and value creation. EMV Capital's investment thesis is realised through
these capital sources:

·     capital-efficient investments through Group balance sheet;

·     fund management of the Evergreen EIS and Martlet Capital Funds;

·     syndicated investments leveraging its network of third-party
investors.

EMV Capital's approach is characterised by its proactive management style,
aiming to advance portfolio companies to critical value inflection points by
actively engaging with them. Companies are supported through Board
representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international
links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

For more information, visit www.emvcapital.com (http://www.emvcapital.com)

About ProAxsis

ProAxsis Limited is a respiratory diagnostics company and a spin-out from
Queens University Belfast. The company has commercialised activity-based
immunoassays targeting Neutrol Elastase (NE) and Proteinase 3, as biomarkers
of lung infection and inflammation in chronic respiratory diseases such as
COPD, cystic fibrosis and bronchiectasis.

This technology is being translated into a point-of-care test (NEATstik®), to
enable ongoing monitoring of active NE levels. The company has a revenue
generating clinical services business line, providing Pharma and CROs with
NEATstik for clinical trials. In addition, the company is exploring a Point of
Care offering, including through a second generation NEATstik.

For more information, visit www. https://proaxsis.com/ (https://proaxsis.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUUSORVSUURAR